{"preliminary_commentary":{"by_channel":{"x_thread":18},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04495309\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"OLIGOMA","nct_id":"NCT04495309","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=oligoma-nct04495309. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"OLIGOMA","arms":[{"description":"Standard of care, i. e. no local radiotherapy in addition to standard systemic therapy (exception: palliative local treatment of symptomatic lesions where indicated)","label":"Standard","type":"NO_INTERVENTION"},{"description":"Standard of care (standard systemic therapy) + study intervention","label":"Experimental","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-06-03","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":87,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Metastases-directed Radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2026-02-27","lead_sponsor":"University Hospital Schleswig-Holstein","official_title":"Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial","overall_status":"COMPLETED","phases":["NA"],"primary_completion_date":{"date":"2025-06-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"First co-primary outcome measure is progression-free survival (PFS)","timeFrame":"at least 12 months after randomization"},{"measure":"Second co-primary outcome measure is quality of life","timeFrame":"12 weeks after randomization"}],"references":[{"citation":"Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J, Klapper W, Schmalz C, Rody A, Maass N, Bauerschlag D, Hessler N, Konig IR, Dellas K, Dunst J. Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol. 2021 Apr 5;28:90-96. doi: 10.1016/j.ctro.2021.03.012. eCollection 2021 May.","pmid":"33912695","type":"DERIVED"}],"start_date":{"date":"2021-03-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04495309"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/oligoma-nct04495309"}